Company intelligence / Profile preview

ki:elements

Saarbrücken, Saarland, Germany

Ownership: Private
Employees: ~25
Development stage: Other

Overview

ki:elements develops and validates remote, speech-based digital biomarkers (not drugs) used as outcome and screening measures in clinical research and healthcare, including a CE‑certified system for neuropsychological testing and a validated speech biomarker for cognition (SB‑C) in early Alzheimer's disease.[3][7][8]

Therapeutic areas: PsychiatryPulmonologyNeurology
Modalities: DeviceNon-pharmacological therapyDigital biomarker
Industry: Digital Health Medical Devices

Partnerships

Pharmaceutical and life science companies for use of speech biomarkers in drug development and clinical trials[2][7]Maastricht University (DeepSpA dementia study)[8]University of Edinburgh (SPeAK dementia study)[8]

Beyond the preview

Go deeper on ki:elements.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ki:elements.

Explore the full profile